US Patent
US8298568 — Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
Formulation · Assigned to Novagali SA · Expires 2027-11-03 · 1y remaining
Vulnerability score
55/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects a well-tolerated oil-in-water emulsion for delivering hydrophobic ingredients, such as pharmaceutical drugs, with a net positive charge.
USPTO Abstract
A well tolerated oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs, wherein the emulsion particles have a net positive charge and comprises 0.001 to 0.1% of a cationic agent, 0 to 1% of a non ionic surfactant and 0 to 0.5% of an anionic surfactant.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.